Tradestie Institutional Equity Comparison Engine

DXR vs AMS โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

DXR Overall Edge

DXR Captures Institutional Edge (2โ€“1 Pillars ยท 7โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Daxor Corporation Common Stock (DXR) driven by superior Growth & Margin, Momentum & Technical while AMS counters with relative strength in Valuation. Fundamentally, DXR trades at 64.5x Forward P/E with -5894.3% operating margin (+25.5% YoY revenue) versus AMS at 44.6x Forward P/E and -7.4% operating margin (+19.2% YoY). In options structure, DXR sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against AMS sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner AMS
DXR 64.5x vs AMS 44.6x Fwd P/E
Growth & Margin Winner DXR
Op Margin -5894.3% vs -7.4% ยท YoY +25.5% vs +19.2%
Momentum & Technical Winner DXR
1Y -38.3% vs -52.2% ยท 52W Pos 2% vs 6%
Options & Structure Winner Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
DXR NASDAQ
Daxor Corporation Common Stock
Surgical & Medical Instruments & Apparatus
$8.36
-1.47% 1D
Market Cap $49.5M
1M Return -16.87%
1Y Return -38.29%
Forward P/E 64.5x
Unified AI Score
52.2 / 100 HOLD
Tech 52.0 Fund 59.0 Flow 50.0 Mom 64.0
AMS NYSE American
American Shared Hospital Services
Services-Medical Laboratories
$1.07
-0.93% 1D
Market Cap $7.2M
1M Return -16.41%
1Y Return -52.23%
Forward P/E 44.6x
Unified AI Score
33.8 / 100 SELL
Tech 24.0 Fund 38.0 Flow 50.0 Mom 30.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: DXR -38.29% AMS -52.23% Spread: +18.96 pp (DXR Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
DXR TTM Op. Margin: -5894.3% AMS TTM Op. Margin: -7.4%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on DXR vs AMS. Trailing 12-month operating profitability (DXR -5894.3% vs AMS -7.4%) and valuation multiples (DXR 64.5x vs AMS 44.6x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: DXR (7) vs AMS (3)
Institutional Metric DXR AMS Criterion Row Winner
Market Capitalization Scale $49.5M $7.2M Larger Scale DXR
Trailing P/E Ratio Valuation 7.7x 44.6x Lower Multiple DXR
Forward P/E Ratio Valuation 64.5x 44.6x Lower Multiple AMS
Revenue Growth (YoY) Growth +25.5% +19.2% Higher Growth DXR
Operating Margin (TTM) Profitability -5894.3% -7.4% Higher Margin AMS
Net Profit Margin Profitability 19861.4% -5.8% Higher Margin DXR
Return on Equity (ROE) Capital Efficiency 14.2% -12.1% Higher ROE DXR
52-Week Range Position Momentum 2% ($8โ€“$15) 6% ($1โ€“$2) Stronger Trend AMS
Beta / 30D Volatility Risk Regime 0.28ฮฒ ยท 32% Vol 0.18ฮฒ ยท 46% Vol Lower Realized Risk DXR
Unified Institutional Score Composite Signal 52.2 / 100 (HOLD) 33.8 / 100 (SELL) Higher Composite DXR

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full DXR vs AMS Buy Guide
DXR UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live DXR Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
AMS UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live AMS Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither DXR nor AMS registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.